600276: JiangSu HengRui
Pharmaceuticals have done well in China over the long-term for many years. Given the quality of JiangSu HengRui and its perpetual growth, there is no reason why this trend should abate over the long haul. This stock is immune to a trade war, yet not immune to business cycle risks, which has caused turbulence for weeks to months before.
I am a little late to publish this article, but it follows up on a previous article that I wrote and posted regarding China's Roaring 2020s.
I am a little late to publish this article, but it follows up on a previous article that I wrote and posted regarding China's Roaring 2020s.
Komentarz:
Just more opportunity to buy at a favorable price:
Komentarz:
Transakcja zamknięta: osiągnięto wyznaczony cel
Komentarz:
Transakcja zamknięta: osiągnięto wyznaczony cel
Capturing the swings of the stock market & currency market. It's a dirty job and equity/currency traders must do it.
